About
Allan Gobbs is the Managing Partner at ATEM Capital, a New York-based Life Sciences venture firm. In recent years, Allan has seen five of his portfolio companies go public on NASDAQ, including notable names like Atea, and Syndax. Additionally, four of his portfolio companies have been successfully acquired, such as Tobira, which was bought by Allergan for up to $1.7 billion, and Amolyt, AI-drug discovery peptide-based company acquired by AstraZeneca for up to $1.05 billion in July 2024. Allan is also the CEO and Chairman of YCare, a digital health integrator in strategic partnership with Dell Technologies and InterSystems, and the Chairman of PGxAI, an AI-powered pharmacogenetics platform. He serves as the President of Virry Health, an AI-powered XR platform focused on tackling mental health conditions, and is a Board Member of Heos Machines, a 3D bioprinting startup. Prior to joining ATEM Capital, Allan was an investment banker at Barclays Capital and other financial institutions, wh
Position in the VCSift Database
- • 4 investors hold the CEO, Managing Partner role in VCSift. Allan Gobbs is one of them.
- • 10,621 investors are based in New York, New York, United States.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Location
- New York, US
Contact Information
Find more investors like Allan
Search Investors